Deals channel feed

Dana­her ap­proached con­tract man­u­fac­tur­er Catal­ent about ac­qui­si­tion – re­port

3 years ago
Manufacturing

Karuna li­cens­es Goldfinch as­sets to com­pete with Boehringer In­gel­heim in neu­ro­science

3 years ago
R&D

Gilead quash­es mi­cro­cap biotech's hope of part­ner­ing on oral Covid-19 drug

3 years ago

UniQure cash­es out $10M up­front to get can­di­date for in­her­it­ed ALS

3 years ago

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

3 years ago
People

Charles Riv­er se­cures $50M ac­qui­si­tion of drug dis­cov­ery tech com­pa­ny

3 years ago
Manufacturing

Bridge­Bio com­pa­ny sells off rare dis­ease can­di­date to Gal­der­ma part­ner

3 years ago

F-star gets down to the wire with $161M sale to Chi­nese buy­er as na­tion­al se­cu­ri­ty con­cerns linger

3 years ago

KSQ Ther­a­peu­tics sells ear­ly-stage tar­get­ed ther­a­pies to Japan's Ono

3 years ago

San­doz signs deal for an­ti­fun­gal from Astel­las in buff-up of an­ti-in­fec­tives port­fo­lio

3 years ago
Pharma

Failed deal, bid­ding war paved the way for Ipsen's $952M rare dis­ease buy­out

3 years ago

How the price of As­traZeneca's buy­out of Cin­Cor fell by $1.4B

3 years ago

Up­dat­ed: J&J ax­es four-year dis­cov­ery al­liance with Mor­phic

3 years ago

Up­dat­ed: Take­da bets $400M cash on col­orec­tal can­cer drug in boost to Chi­na's Hutchmed

3 years ago
China

Sesen takes next step af­ter in­vestor at­tack, calls for share­hold­er vote to ap­prove merg­er

3 years ago
Financing

Disc Med­i­cine pays $10M up­front for mon­o­clon­al an­ti­body for rare blood dis­or­der, can­cer

3 years ago

Small-cap CNS out­fit inks API deal for pre­clin­i­cal MEK in­hibitor

3 years ago
Manufacturing

Off Ed­i­tas’ shelves, iNK cell ther­a­pies float to Shore­line

3 years ago
Startups
Cell/Gene Tx

Sun Phar­ma buys out Con­cert, and its alope­cia drug, for $576M

3 years ago
R&D

Am­gen ex­tends au­toim­mune pact with small Michi­gan biotech

3 years ago
Startups
Pharma

Pathalys inks de­vel­op­ment deal with Abing­worth com­pa­ny, rais­ing $150M

3 years ago
Financing

Ex-US Com­merce Sec­re­tary Wilbur Ross pairs his SPAC with Alzheimer's biotech

3 years ago
Startups
Diagnostics

Bank­rupt Phase­Bio set­tles with in­vestor-part­ner, hand­ing off late-stage drug

3 years ago
Law

PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

3 years ago
Pharma
First page Previous page 41424344454647 Next page Last page
A service from the Financial Times